-year maximum for each term and a limit of three consecutive terms unless the board of directors views that holding an office more than three consecutive terms would not affect the director's independence
price of the Company’s shares listed on the Stock Exchange of Thailand – MAI (“SET”) for the previous 15 consecutive business days prior to the resolution of the Board of Directors’ Meeting proposing the
Administration (CFDA) at the beginning of 2 0 1 8 as the Company had to redesign its packaging to comply with the requirements of the license. Furthermore, the Company also found it necessary to adjust its sales
year to be in parallel with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for
ongoing outbreak of COVID–19, forcing many customers to adjust their working method which have an effect on the operation and delivery of the Company's projects that cause the operation to be delayed than
reducing production cost and also negotiating with customers to review and adjust selling price every quarter. 2.2. Distribution costs for 2018 was in the amount of 4.95 million baht, increased by 1.16
with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for certain expenses that the
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
that the Company managed to properly slash sales expenses from the previous year to be in parallel with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and
สะสมที่ลดลงจากผลกระทบของการเปลี่ยนแปลงนโยบายการบัญชี ฉบับที่ 9 และฉบับที่ 16 จำนวน 8 ล้าน บาท (one-time adjust) ณ วันที่ 31 มีนาคม 2563 อัตราหนี้สินต่อส่วนของผู้ถือหุ้นของกลุ่มบริษัทฯ (D/E ratio) เท่ากับ